pacDNA strives to use our Brushield™ oligonucleotide enhancer technology to bring life-changing medicines to patients. Our technologies enable rapid candidate validation with significantly greater accumulation in target organs, enhanced potency, better safety, and improved pharmacological profile. While we are seeking partnership and out-licensing opportunities, we are also internally  developing a robust pipeline of clinical-stage assets that leverages the unique benefits of the Brushield™ platform with favorable clinical development pathways and a significant unmet clinical need.